title: [Effects of small interfering RNA specific for Her-2 gene on biological behavior of ovarian carcinoma cell].
abstract: OBJECTIVE
  To explore the effects of small interfering RNA (siRNA) specific for Her-2 gene on biological behavior of ovarian carcinoma cell.
  
  
  METHODS
  Her-2 siRNA recombinant plasmid and negative control plasmid were transfected into packing cell line PT67 by liposome, and PT67 was selected by puromycin later. SKOV3 was infected by the virus supernatant of stably transfected PT67 cell lines, and the stably transfected SKOV3 cell lines (SKOV3/siRNA, SKOV3/siRNA-negative) established by selection with puromycin were investigated in terms of the reduction levels of Her-2 mRNA and p185 by RT-PCR and immunohistochemistry. Cell proliferation was assayed with methyl thiazolyl tetrazolium, and cell cycle distribution and cell apoptosis were assayed with flow cytometry. The tumor growth of the null mice was analyzed after injection of SKOV3/siRNA and SKOV3/siRNA-negative into the skin.
  
  
  RESULTS
  (1) The stable SKOV3 cell lines with a persistent silence of Her-2 gene were established. (2) The percentages of SKOV3/siRNA in G(0)/G(1) phase and S phase were 68.6%, 15.1% respectively; while the percentages of SKOV3/siRNA-negative in G(0)/G(1) phase and S phase were 55.8%, 23.3%. (3) The percentage of SKOV3/siRNA in early apoptosis was (10.500 +/- 0.250)%, while the percentage of SKOV3/siRNA-negative was (0.340 +/- 0.010)% (P < 0.01). (4) Compared with SKOV3/siRNA-negative, the proliferation of SKOV3/siRNA was delayed obviously (P < 0.05), and the growth of the corresponding implanted tumor slowed down significantly (P < 0.01).
  
  
  CONCLUSIONS
  siRNA can inhibit the expression of Her-2 gene effectively, which restrains the biological behavior of ovarian carcinoma cell.
authors.affiliation: Anhui Province Key Laboratory of Molecular Medicine, Hefei 230001, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhou
authors.forename: Bin
authors.initials: B
authors.lastname: Ling
authors.forename: Ding-Qing
authors.initials: DQ
authors.lastname: Feng
authors.forename: Zhi-Xiang
authors.initials: ZX
authors.lastname: Cheng
authors.forename: Guo-Dong
authors.initials: GD
authors.lastname: Shen
authors.forename: Ting
authors.initials: T
authors.lastname: Gao
authors.forename: Yong-Yun
authors.initials: YY
authors.lastname: Shi
authors.forename: Mei-Mei
authors.initials: MM
authors.lastname: Wang
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Zhao
authors.forename: Huai-Ping
authors.initials: HP
authors.lastname: Zhu
mesh_terms: D000818:Animals; D017209:Apoptosis; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2; D007150:Immunohistochemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D009366:Neoplasm Seeding; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D034622:RNA Interference; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D034741:RNA, Small Interfering; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D014162:Transfection
chemical_list: D012333:RNA, Messenger; D034741:RNA, Small Interfering; D018719:Erb-b2 Receptor Tyrosine Kinases